Focus this week: sorting out the pipeline under research of overseas pharmaceutical enterprises in 2021
This week, we focused on 19 multinational pharmaceutical companies (Alberta, Amgen, AstraZeneca, Bayer, Bojian, BMS, Gilead, GSK, Johnson & Johnson, Eli Lilly, Moderna, Merck, Novo Nordisk, Novartis, Pfizer, regenerant, Roche, Sanofi and Takeda), and comprehensively sorted out the drug candidates and product pipelines in the stage of clinical development publicly disclosed by various pharmaceutical companies on the official website. Through the in-depth analysis of more than 1000 clinical trials, this paper depicts the clinical R & D pattern of multinational pharmaceutical enterprises. Select the four most notable diseases: tumor, covid-19, nervous system and autoimmunity for systematic interpretation, and analyze the trend of global new drug research and development.
Overview of core conclusions:
According to the disease field, anti-tumor maintains the most popular position, accounting for 45% of the total number of R & D pipelines; Immune inflammation and nervous system drugs entered the top five with 13% and 7% of R & D proportion; The number of covid-19 medication pipelines increased significantly, accounting for 3%;
According to the product type, biological drugs have become the development trend, and emerging molecules such as double antibodies, protac and ADC can be expected in the future (double antibodies are mostly concentrated in CD3, CD20 and PSMA, ADC is mostly distributed in HER2 and trop2, while protac is popular in Er, AR and Btk); Cell therapy focuses on hematoma, and the upgrading of preparation technology promotes the development of industrialization; Gene therapy is widely used in rare tumors and nervous system drugs.
According to molecular targets and immune checkpoints, tumor immunotherapy is gradually popularized, CD3 double antibody products bloom, and BCMA targeted cell therapy is deeply expected; SHP2 and other targets emerged in small molecule inhibitors.
Tumor field:
In terms of indications, hematoma R & D project is the most attractive subdivision field. The hematoma pipeline under research in clinical phase II is 7% higher than that in clinical phase III, which is more difficult to develop;
The number of targeted drugs is relatively small in the later stage of development according to the type of research and development of monoclonal antibodies; Emerging technologies such as dual antibody, ADC, cell therapy, protac and molecular glue have developed vigorously, and their proportion in clinical phase I has increased significantly.
In terms of sub targets, the number of CD3 targeted molecules is significantly ahead of other targets, and most of them are bispecific antibodies; CD19 and BCMA are important biomarkers in the field of blood tumors. In addition to cell therapy, related products also have layout of new technologies such as dual antibody and ADC; SHP2, sting and other targets have attracted much attention in early research;
From the perspective of branches, BMS, Merck, Roche and Novartis constitute four major leaders in anti-tumor R & D, accounting for half of the tumor drug R & D pipeline.
\u3000\u3000COVID-19：
Covid-19 vaccine: the recombinant protein vaccine of GSK / Sanofi is on the line. Moderna has developed beta, Delta, Omicron variant specific vaccine and multivalent vaccine, refrigerated and stable second-generation upgraded vaccine, and two in one single dose vaccine against covid-19 virus and seasonal influenza virus;
Covid-19 neutralizing antibody: AstraZeneca covid-19 long-acting antibody combination evusheld has become the first neutralizing antibody combination for prevention; Neutralizing antibody products that can enhance the function of virus specific T cells are arranged in the early clinical pipeline of GSK.
Covid-19 small molecule: the target focuses on RdRp and 3CL protease, and Merck and Pfizer lead the progress. Pfizer paxlovid is used in covid-19 standard risk patients, family exposed people and children, and clinical trials are being carried out; Gilead has started the phase I clinical research and development project of redcivir prodrug variant gs-5245.
Market review of innovative medicine stocks in the pharmaceutical sector:
Sinocelltech Group Limited(688520) -u, Hunan Nucien Pharmaceutical Co.Ltd(688189) , Guangdong Zhongsheng Pharmaceutical Co.Ltd(002317) , Livzon Pharmaceutical Group Inc(000513) , Luoxin Pharmaceuticals Group Stock Co.Ltd(002793) . The last five are Frontier Biotechnologies Inc(688221) -u, Jenkem Technology Co.Ltd(688356) , Staidson(Beijing) Biopharmaceuticals Co.Ltd(300204) , Shan Dong Kexing Bioproducts Co.Ltd(688136) , Brightgene Bio-Medical Technology Co.Ltd(688166) .
The top 5 gainers and losers in the pharmaceutical innovative drug sector of Hong Kong stocks this week are Deqi pharmaceutical-b, cornerstone pharmaceutical-b, Nuo chengjianhua-b, kangfang biology-b and Xiansheng pharmaceutical. The last five are Peijia medical-b, tengshengbo medicine-b, Beihai kangcheng-b, Yaoming junuo-b, Shanghai Junshi Biosciences Co.Ltd(688180) .
IPO this week: Ruike Biology – the first share of HPV vaccine in Hong Kong stock market
Risk tips: 1) negative policies continue to exceed expectations; 2) The growth rate of the industry was lower than expected.
